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Abstract:
Hepatitis C (HCV) is the most common blood-borne viral infection 
in the United States with an estimated prevalence of 2.4 million 
people[1]. Oklahoma has an estimated 54,000 chronic cases of 
hepatitis C and has the highest exposure rate of all 50 states[2]. 
Even with increased screening and access to medications, gaps 
exist in the cascade of care for patients with hepatitis C with 
approximately 40% of diagnosed patients not having been 
prescribed antiviral treatment[3]. Treatment of hepatitis C has 
been associated with a reduction in liver failure, a reduction in 
hepatocellular carcinoma, and a reduction in all-cause mortality.
We attempted to call 24 patients who 
were identified as “lost to follow up” 
with an elevated hepatitis C viral load. 
We were unable to contact 9; We then 
instructed the remaining 15 patients to 
schedule an appointment for further 
workup and/or treatment. 8 out of the 
15 patients were scheduled with an 
OSU Family Medicine provider for 
further followup. 
Our data revealeda major barrier to patients progressing through the 
hepatitis C treatment cascade is reliable communication between patient 
and medical team. Pre-treatment testing was another significant barrier 
due to the sequence of labs required for workup, and a lack of reflexive 
lab studies. Treatment being declined by insurance companies iremains 
problematic, despite overwhelming evidence of treatment efficacy 
administered by primary care providers; many of these payer sources 
require the patient be seen by a specialist for HCV treatment. Considering 
how there has been a substantial increase in access and availability to 
hepatitis C treatment, allowing primary care physicians to administer 
treatment would greatly expand access for this patient population to be 
cured.
Our intervention resulted in 8 of the 24 patients scheduling further 
appointments for workup or treatment. This simple intervention led to a 
33% follow up rate. Further interventions may include automatic reflex 
testing to shorten time from diagnosis to treatment.
Results
Background
At risk for exposure[5]:
-born between 1945-1965
-high risk activity (IV/intranasal drug use, MSM)
-recipient of potentially contaminated blood products
-history of HIV, hepB, or other bloodborne illness
-past or current use of hemodialysis
-history of incarceration
-biochemical evidence of chronic liver disease
-extrahepatic manifestations associated with chronic 
hepatitis C (porphyria cutanea tarda, lichen plans, etc.)
Labs needed prior to treatment selection:
-viral load, genotype, CBC, CMP, liver US (with 
possible fibrosure/biopsy/ or more imaging), INR, HIV 
and HBV status
Treatment specific to genotype:
-routine monitoring based on antiviral agent
Test of cure:
-performed 12 weeks after completion of treatment
With increased access to curative medications and better 
treatment options for hepatitis C, our goal is to determine the 
barriers to treatment for those who have been diagnosed with 
hepatitis C. By removing barriers to hepatitis C treatment, we 
can decrease the incidence and prevalence of this disease. 
Furthermore, by decreasing the disease burden of hepatitis C, 
we can decrease rates of liver disease, cirrhosis, hepatocellular 
carcinoma, and associated morbidity and mortality.
We conducted a retrospective review of lab data from the 
electronic health record for patients seen by the OSU Family 
Medicine department. Patients who had a detectable HCV viral 
load lab drawn between January 1, 2018 to March 31, 2019 
was generated. From this list we identified those patients who 
were not actively being treated for HCV. Our intervention was 
contacting these patients to assess any barriers which may 
have delayed treatment, and evaluate how effective this phone 
call is in connecting patients with the proper resources to 
proceed to the next step in work up and treatment.
The most common Barrier to 
individuals diagnosed with 
hepatitis C in our panel were 
identified as:
1) Patient inability to complete all 
lab work and imaging.
2) Specialist referral requirement 
by some insurance companies.
3) Current medical comorbidities 
at time of phone call.
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